WIN 18,446 treatment was associated with the decreased expression of the gut homing α4ß7 integrin on activated CD4+ T cells [23], which is intriguing because some of the most effective biologics for the treatment of IBD are monoclonal antibodies targeting α4ß7 integrin [1]. Here, CD4 is linked to inflammatory bowel disease.